Technical Analysis for NEO - NeoGenomics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 14.99 | -0.93% | -0.14 |
Earnings due: May 23
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Fell Below 200 DMA | Bearish | -0.93% | |
Stochastic Sell Signal | Bearish | -0.93% | |
Slingshot Bullish | Bullish Swing Setup | -0.93% | |
Gapped Up | Strength | -0.93% | |
Down 3 Days in a Row | Weakness | -0.93% |
Alert | Time |
---|---|
Possible NR7 | about 5 hours ago |
60 Minute Opening Range Breakout | about 8 hours ago |
60 Minute Opening Range Breakdown | about 9 hours ago |
Down 1% | about 9 hours ago |
Fell Below Previous Day's Low | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/23/2024
NeoGenomics, Inc. Description
NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company's trademarks include NeoFISH, NeoFlow, NeoSITE, NeoArray, NeoType, and MelanoSITE. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Cancer Biology Disease Telehealth Telemedicine Genetics Genomics Lymphoma Medical Test Lab Testing Leukemia Bladder Cancer Solid Tumor Cancers Flow Cytometry Anatomical Pathology Laboratory Techniques Hybridization Cytogenetics
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.22 |
52 Week Low | 11.045 |
Average Volume | 771,426 |
200-Day Moving Average | 15.27 |
50-Day Moving Average | 14.84 |
20-Day Moving Average | 14.74 |
10-Day Moving Average | 15.39 |
Average True Range | 0.67 |
RSI (14) | 50.74 |
ADX | 19.91 |
+DI | 25.83 |
-DI | 20.79 |
Chandelier Exit (Long, 3 ATRs) | 14.10 |
Chandelier Exit (Short, 3 ATRs) | 15.36 |
Upper Bollinger Bands | 16.26 |
Lower Bollinger Band | 13.22 |
Percent B (%b) | 0.58 |
BandWidth | 20.61 |
MACD Line | 0.21 |
MACD Signal Line | 0.15 |
MACD Histogram | 0.0585 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 15.47 | ||||
Resistance 3 (R3) | 15.48 | 15.33 | 15.39 | ||
Resistance 2 (R2) | 15.33 | 15.21 | 15.33 | 15.36 | |
Resistance 1 (R1) | 15.16 | 15.13 | 15.09 | 15.15 | 15.34 |
Pivot Point | 15.01 | 15.01 | 14.97 | 15.01 | 15.01 |
Support 1 (S1) | 14.84 | 14.89 | 14.77 | 14.83 | 14.64 |
Support 2 (S2) | 14.69 | 14.81 | 14.69 | 14.62 | |
Support 3 (S3) | 14.52 | 14.69 | 14.59 | ||
Support 4 (S4) | 14.51 |